

Talazoparib Dose Modification

Disclaimers

- This document has been approved for use in Australia by Pfizer Oncology Medical colleagues in response to unsolicited requests on this topic, and may not be distributed
- This document includes information of an off-label nature. Pfizer does not suggest or recommend the use of any Pfizer products in any manner other than as described in the TGA approved Prescribing Information (www.tga.gov.au)
- Talazoparib has not been approved by the TGA for use in prostate cancer and has not been found safe or effective

Dose Modification Tables

Table 1. Recommended dose reduction levels for adverse reactions in mCRPC when used in combination with enzalutamide¹

Dose Reductions	Dose Level
Recommended starting dose ²	0.50 mg once daily
1 st dose reduction ^a	0.35 mg once daily
2 nd dose reduction	0.25 mg once daily
3 rd dose reduction	0.10 mg once daily

Table 2. Recommended dose levels in mCRPC when used after 6 weeks of enzalutamide discontinuation^{1,b}

Talazoparib dose at enzalutamide discontinuation	Talazoparib levels 6 weeks from enzalutamide discontinuation
0.50 mg	1.00 mg once daily
0.35 mg	0.75 mg once daily
0.25 mg	0.50 mg once daily
0.10 mg	0.20 mg once daily

mCRPC: metastatic castration-resistant prostate cancer; For enzalutamide dose reductions, please refer to the TGA website³

^aStarting dose for patients with moderate renal impairment (eGFR 30-59 mL/min/1.73m² based on [MDRD](#) equation)¹

^bAfter escalation, talazoparib dose can be reduced in 0.25 mg decrements to manage adverse events. Patients on 0.20 mg can dose reduce to 0.10 mg¹

References

1. Agarwal N *et al.* Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. *The Lancet*. 2023. DOI: [https://doi.org/10.1016/S0140-6736\(23\)01055-3](https://doi.org/10.1016/S0140-6736(23)01055-3)
2. Agarwal N, *et al.* ASCO Annual Meeting 2019, Abstract 5076
3. [Therapeutic Goods Administration \(TGA\)](#) (Accessed 18/09/2023)